Provider Briefing: Elevidys Access and Availability in 2026

The availability landscape for Elevidys (Delandistrogene Moxeparvovec-rokl) has changed significantly since its initial FDA approval. For providers managing patients with Duchenne muscular dystrophy (DMD), staying current on the regulatory, safety, and access developments is essential for informed clinical decision-making and effective patient counseling.

This briefing covers the key changes, their prescribing implications, and practical tools for helping patients navigate access.

Timeline of Key Events

Understanding the sequence of events helps contextualize the current access environment:

• June 2023: FDA grants accelerated approval to Elevidys for ambulatory DMD patients aged 4-5 years based on micro-dystrophin expression
• June 2024: FDA expands approval to traditional approval for ambulatory patients and accelerated approval for non-ambulatory patients aged 4 and older
• June 2025: Sarepta voluntarily halts shipments for non-ambulatory patients following expert committee review of liver safety signal
• July 2025: Sarepta extends voluntary pause to all Elevidys shipments following informal FDA request
• Late 2025: FDA approves updated prescribing information with Boxed Warning; indication restricted to ambulatory patients; shipments resume for eligible ambulatory patients

Prescribing Implications of Updated Labeling

Boxed Warning: Hepatotoxicity

The updated labeling includes a Boxed Warning for the risk of serious liver injury and acute liver failure, including fatal outcomes. Key clinical considerations:

• Fatal acute liver failure was reported in non-ambulatory DMD patients
• Life-threatening mesenteric vein thrombosis with bowel ischemia, necrosis, and portal hypertension reported as complications of serious non-fatal acute liver injury
• Enhanced hepatic monitoring is now required before, during, and after infusion
• Baseline liver function testing must be completed and documented prior to treatment

Restricted Indication

Elevidys is now indicated only for ambulatory patients aged 4 years and older with a confirmed mutation in the DMD gene amenable to treatment. Key exclusion criteria include:

• Non-ambulatory patients (indication withdrawn)
• Patients with DMD gene deletions affecting exons 8 or 9
• Patients with preexisting liver impairment
• Patients with recent vaccinations
• Patients with recent or active infections

Updated Corticosteroid Regimen

The revised prescribing information includes an updated corticosteroid protocol:

• Corticosteroids must be initiated the day before infusion
• Minimum 60-day corticosteroid course post-infusion (previously less defined)
• Dose adjustments based on clinical presentation and monitoring results
• Consider additional immunomodulatory treatment (e.g., calcineurin inhibitors) based on patient's clinical presentation and medical history

Enhanced Safety Monitoring

The updated label specifies more rigorous monitoring requirements:

• Hepatic function: Baseline and serial liver function tests with defined monitoring intervals
• Cardiac monitoring: Troponin-I levels (acute serious myocarditis has been observed)
• Platelet counts: Thrombocytopenia monitoring
• Infection surveillance: Increased susceptibility to serious infections due to immunosuppressive regimen

Current Availability Picture

As of early 2026, the availability situation can be summarized as follows:

• Ambulatory patients: Elevidys shipments have resumed; treatment centers are accepting qualified patients
• Non-ambulatory patients: Not available; indication withdrawn
• Treatment centers: Limited to specialized neuromuscular disease centers with gene therapy infrastructure
• Weight-based kits: Multiple kit sizes including the 21.5-22.4 kg kit are in production; specific kits must be matched to patient weight at time of treatment

The number of active treatment centers remains limited, creating potential scheduling bottlenecks. Providers should begin the referral and authorization process well in advance of the desired treatment window.

Cost and Access Considerations

At a wholesale acquisition cost (WAC) of $3.2 million, Elevidys presents significant payer challenges:

• Prior authorization is universally required and typically involves multi-step review
• Peer-to-peer reviews are common; be prepared to discuss clinical rationale with payer medical directors
• Appeals are frequently necessary; document ambulatory status, genetic confirmation, and clinical justification thoroughly
• Site of care: Most payers classify Elevidys as a medical benefit (not pharmacy benefit), which affects the authorization pathway

For a detailed guide on helping patients manage costs, see our provider's guide to saving money on Elevidys.

Tools and Resources for Providers

SareptAssist (Provider Services)

Sarepta's SareptAssist program offers dedicated provider support including:

• Prior authorization assistance and template documentation
• Peer-to-peer review support
• Treatment center network information
• Patient eligibility verification

Contact: 1-888-727-3782

Medfinder for Providers

Medfinder's provider platform offers tools for tracking medication availability and connecting patients with treatment access resources. For a gene therapy like Elevidys, this can help streamline the process of identifying active treatment centers and current availability status.

Patient Advocacy Organizations

Partnering with advocacy organizations can provide additional support for your patients:

• Parent Project Muscular Dystrophy (PPMD): Offers care navigation, educational resources, and peer support for DMD families
• Muscular Dystrophy Association (MDA): Operates MDA Care Centers and provides treatment access support

Alternative Treatment Considerations

For patients who are ineligible for Elevidys or facing extended access timelines, ensure optimization of available therapies:

• Deflazacort (Emflaza): First-line corticosteroid for DMD; well-established evidence base
• Exon-skipping therapies: Eteplirsen (exon 51), Casimersen (exon 45), Viltolarsen (exon 53) — confirm mutation amenability through genetic testing
• Clinical trials: Monitor ClinicalTrials.gov for emerging gene therapy and novel mechanism trials

For more details, see our alternatives overview.

Looking Ahead

Several developments may affect the Elevidys access landscape in the coming months:

• Ongoing post-marketing safety surveillance may lead to additional labeling updates
• Payer policies continue to evolve as more real-world treatment data becomes available
• Additional treatment centers may begin offering Elevidys as gene therapy infrastructure expands
• Next-generation gene therapy candidates for DMD continue through clinical development

Final Thoughts

The Elevidys safety events of 2025 have fundamentally changed the risk-benefit conversation for DMD gene therapy. Providers play a critical role in helping families understand the current evidence, navigate the complex access process, and make informed treatment decisions.

For additional clinical information, review our articles on Elevidys mechanism of action, drug interactions, and our provider guide to helping patients find Elevidys.